Table 1.
Demographics, comorbidities and treatment features
| DMT | Patients (n) | ITPs | Age (years) | Females (n) | Charlson Comorbidity Index | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2018 | 2019 | 2020 | 0 | 1–2 | 3–4 | ≥ 5 | ||||
| Ocrelizumab | 398 | 27 | 281 | 91 | 45.74 ± 10.98 | 224 | 395 | 5 | – | – |
| Alemtuzumab | 31 | 18 | 13 | 0 | 35.39 ± 8.31 | 21 | 31 | – | – | – |
| Natalizumab | 261 | 82 | 72 | 108 | 34.05 ± 10.99 | 183 | 360 | 2 | – | – |
| Cladribine | 30 | 0 | 26 | 4 | 43.13 ± 11.97 | 22 | 30 | – | – | – |
| Fingolimod | 399 | 197 | 139 | 65 | 39.17 ± 11.42 | 259 | 398 | 3 | – | – |
| Teriflunomide | 305 | 176 | 71 | 59 | 48.51 ± 11.18 | 202 | 302 | 4 | – | – |
| Dimethyl fumarate | 587 | 269 | 196 | 123 | 38.98 ± 12.10 | 408 | 583 | 3 | 1 | – |
| Interferon beta1a im | 87 | 63 | 14 | 10 | 48.84 ± 12.73 | 59 | 87 | – | – | – |
| Interferon beta1b | 67 | 52 | 14 | 7 | 52.12 ± .10.10 | 40 | 67 | – | – | – |
| Glatiramer acetate | 239 | 175 | 182 | 41 | 46.73 ± 11.66 | 164 | 236 | 3 | – | – |
| Peg-interferon beta1a | 80 | 39 | 28 | 13 | 39.86 ± 13.62 | 60 | 80 | – | – | – |
| Interferon beta1a sc | 262 | 179 | 48 | 36 | 40.88 ± 12.54 | 199 | 262 | 1 | – | – |